When "Pre-IPO" Access Becomes a Vehicle for Fraud: Lessons from a Recent SEC Enforcement Action

The SpaceX IPO in June 2026 was the largest in history. It was also, for hundreds of retail investors, the moment they discovered that the pre-IPO shares they thought they owned were not what they had been told -- and that the fees they had been charged were nothing like what had been disclosed.

The SEC filed its complaint against Andrew Spaventa and his network of entities on August 14, 2026. I read it carefully. What follows is not a legal analysis -- I'm not acting as anyone's counsel here. It's a compliance professional's observations about what went wrong, why it matters for the broader pre-IPO market, and what registered investment advisers and their investors should understand right now.

Illustrated representation of a SpaceX rocket,

What the complaint alleges

The SEC alleges that Spaventa raised more than $74 million from over 800 mostly retail investors -- including more than 100 retirees -- through eleven private funds purportedly holding pre-IPO securities in companies including SpaceX, Anduril, Stripe, and Perplexity AI. The alleged scheme had several layers.

First, hidden markups. Spaventa's entities acquired pre-IPO securities and then sold them to the funds at substantially higher prices -- on average approximately 46% above acquisition cost. These markups were passed on to investors as embedded fees in the unit price they paid. Meanwhile, investors were told they were paying either no upfront fees or fees of no more than 12.5%.

Second, misrepresentations about value. Investors were told the unit prices reflected market value. In reality, according to the complaint, prices were set based on revenue targets. An internal email cited in the complaint makes this explicit -- Spaventa allegedly wrote that "in order to maintain a 20% margin," the fund "must charge at least 25% over purchase price." That is not a valuation methodology. That is a margin calculation dressed up as one.

Third, fabricated track records. Sales agents were allegedly scripted to claim extraordinary returns of 200% to 1,000% from prior investments -- including investments in Airbnb, Palantir, and Coinbase -- that the funds had never actually made. SpaceX was among the names invoked to add credibility to the pitch.

Fourth, manufactured scarcity. Scripts directed agents to tell investors that available units were nearly exhausted regardless of actual inventory -- classic high-pressure sales tactics designed to override investor skepticism.

Why the SpaceX IPO makes this particularly significant

SpaceX was one of the most sought-after pre-IPO names in the market for years. The allure was real -- the company's growth trajectory was extraordinary and access to pre-IPO shares was genuinely limited for most retail investors. That legitimate scarcity and genuine investor desire created the exact conditions that bad actors exploit.

When a high-profile liquidity event finally occurs -- as it did in June 2026 -- investors who believed they held pre-IPO shares in the right companies at reasonable prices will discover the reality of what they actually paid and what they actually own. For the investors caught in this alleged scheme, that moment of reckoning is now arriving.

This is not the first time the pre-IPO space has attracted fraud. The complaint itself references StraightPath Venture Partners, a prior SEC enforcement action where principals were ultimately convicted and sentenced to between eight and eleven years in prison. Spaventa allegedly used StraightPath's own offering documents as a template -- including the misleading fee language.

What this means if you are a registered investment adviser

If you advise clients who have invested in pre-IPO vehicles -- or if clients are asking you about such opportunities -- the Spaventa complaint is worth reading as a due diligence checklist in reverse. Every red flag alleged in this complaint is something a careful adviser should be looking for.

Ask how the fund acquires its pre-IPO securities. Direct purchases from shareholders carry different risks and cost structures than investments in other funds that purport to hold those securities. The complaint alleges that over 90% of Spaventa's pre-IPO securities were acquired through investments in other funds -- not directly from shareholders -- a fact allegedly misrepresented to investors.

Ask exactly how unit prices are determined and demand documentation. "Market value" is not self-defining. If a fund cannot explain its pricing methodology in concrete terms and reconcile it against available secondary market data, that is a material gap.

Ask for complete fee disclosure including any markups applied before the fund acquires the underlying securities. The most common investor protection failure in the pre-IPO space is not the disclosed fee -- it is the undisclosed markup embedded in the price.

Verify performance claims independently. Extraordinary return claims based on investments the fund never made are not just aggressive marketing -- they are potentially fraudulent. If a track record cannot be verified against audited records, treat it as unverified.

What the SEC will be looking at

The SEC's examination program will follow this enforcement action. Advisers who offer or recommend pre-IPO investment vehicles should expect examiners to probe fee disclosure, pricing methodology, the accuracy of marketing materials, and whether performance representations are substantiated. The principal transaction requirements of the Advisers Act -- which require written consent before an adviser trades with a client from its own account -- will be front of mind for any examiner reading this complaint.

If your clients have exposure to pre-IPO vehicles and you have not reviewed the disclosure documents carefully, now is the time.

The bottom line

The pre-IPO market offers real opportunities for sophisticated investors. It also creates conditions -- limited information, illiquid assets, difficult-to-verify pricing -- that reward bad actors and punish investors who do not ask the right questions. The SpaceX IPO that so many investors dreamed about has arrived. For some of them, it arrived with a very different outcome than they were promised.

The SEC's complaint is a reminder that access to exciting investments does not substitute for disclosure, and that "trust us, we have no hidden fees" is never a compliance program.

Susan Kim is a former SEC examiner and the founder of No Bad Acts LLC, a compliance advisory firm serving investment advisers and private fund managers. She can be reached at skim@nobadacts.com. This post is for informational purposes only and does not constitute legal advice.